eprintid: 10126218 rev_number: 22 eprint_status: archive userid: 608 dir: disk0/10/12/62/18 datestamp: 2021-04-22 15:44:04 lastmod: 2022-06-06 11:14:16 status_changed: 2021-04-22 15:44:04 type: article metadata_visibility: show creators_name: Chong, JR creators_name: Ashton, NJ creators_name: Karikari, TK creators_name: Tanaka, T creators_name: Saridin, FN creators_name: Reilhac, A creators_name: Robins, EG creators_name: Nai, Y-H creators_name: Vrooman, H creators_name: Hilal, S creators_name: Zetterberg, H creators_name: Blennow, K creators_name: Lai, MKP creators_name: Chen, CP title: Plasma P‐tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease ispublished: pub divisions: UCL divisions: B02 divisions: C07 divisions: D07 divisions: F86 keywords: Alzheimer's disease, amyloid beta, biomarkers, cerebrovascular disease, non-Alzheimer's pathophysiology, phosphorylated tau, plasma note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. abstract: INTRODUCTION: There is increasing evidence that phosphorylated tau (P-tau181) is a specific biomarker for Alzheimer's disease (AD) pathology, but its potential utility in non-White patient cohorts and patients with concomitant cerebrovascular disease (CeVD) is unknown. METHODS: Single molecule array (Simoa) measurements of plasma P-tau181, total tau, amyloid beta (Aβ)40 and Aβ42, as well as derived ratios were correlated with neuroimaging modalities indicating brain amyloid (Aβ+), hippocampal atrophy, and CeVD in a Singapore-based cohort of non-cognitively impaired (NCI; n = 43), cognitively impaired no dementia (CIND; n = 91), AD (n = 44), and vascular dementia (VaD; n = 22) subjects. RESULTS: P-tau181/Aβ42 ratio showed the highest area under the curve (AUC) for Aβ+ (AUC = 0.889) and for discriminating between AD Aβ+ and VaD Aβ- subjects (AUC = 0.903). In addition, P-tau181/Aβ42 ratio was associated with hippocampal atrophy. None of the biomarkers was associated with CeVD. DISCUSSION: Plasma P-tau181/Aβ42 ratio may be a noninvasive means of identifying AD with elevated brain amyloid in populations with concomitant CeVD. date: 2021-10 date_type: published official_url: https://doi.org/10.1002/alz.12332 oa_status: green full_text_type: other language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 1857930 doi: 10.1002/alz.12332 lyricists_name: Zetterberg, Henrik lyricists_id: HZETT94 actors_name: Allington-Smith, Dominic actors_id: DAALL44 actors_role: owner full_text_status: public publication: Alzheimer's & Dementia volume: 17 number: 10 pagerange: 1649-1662 event_location: United States citation: Chong, JR; Ashton, NJ; Karikari, TK; Tanaka, T; Saridin, FN; Reilhac, A; Robins, EG; ... Chen, CP; + view all <#> Chong, JR; Ashton, NJ; Karikari, TK; Tanaka, T; Saridin, FN; Reilhac, A; Robins, EG; Nai, Y-H; Vrooman, H; Hilal, S; Zetterberg, H; Blennow, K; Lai, MKP; Chen, CP; - view fewer <#> (2021) Plasma P‐tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. Alzheimer's & Dementia , 17 (10) pp. 1649-1662. 10.1002/alz.12332 <https://doi.org/10.1002/alz.12332>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10126218/3/Zetterberg_Chong.pdf